Name (Synonyms) | Correlation | |
---|---|---|
drug3090 | Vitamin Super B-Complex Wiki | 0.55 |
drug11 | 0.9%NaCl Wiki | 0.32 |
drug1337 | Hyperbaric oxygen Wiki | 0.32 |
drug2872 | Test: Favipiravir 200 mg (LOQULAR) Wiki | 0.32 |
drug2069 | Patient sampling Wiki | 0.32 |
drug2000 | Other drugs Wiki | 0.32 |
drug3196 | bidirectional oxygenation mouthpiece Wiki | 0.32 |
drug2398 | Reference: Favipiravir 200 mg (Avigan) Wiki | 0.32 |
drug2657 | Sofosbuvir and Ledipasvir Wiki | 0.32 |
drug2566 | Sarilumab SAR153191 Wiki | 0.32 |
drug2178 | Plaquenil 200Mg Tablet Wiki | 0.32 |
drug654 | Chloroquine Wiki | 0.22 |
drug1862 | Niclosamide Wiki | 0.22 |
drug335 | BCG Vaccine Wiki | 0.18 |
drug1489 | Ivermectin Wiki | 0.14 |
drug2122 | Placebo Wiki | 0.11 |
drug1087 | Favipiravir Wiki | 0.07 |
drug752 | Convalescent Plasma Wiki | 0.06 |
drug313 | Azithromycin Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D016739 | Behavior, Addictive NIH | 0.16 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.12 |
D019966 | Substance-Related Disorders NIH | 0.11 |
D018352 | Coronavirus Infections NIH | 0.10 |
D014777 | Virus Diseases NIH | 0.04 |
D007239 | Infection NIH | 0.03 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.03 |
D011014 | Pneumonia NIH | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0030858 | Addictive behavior HPO | 0.16 |
HP:0002090 | Pneumonia HPO | 0.02 |
There are 10 clinical trials
Trial to evaluate the efficacy and safety of NTZ for post-exposure prophylaxis of COVID-19 and other VRIs in elderly LTCF residents.
Description: The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period.
Measure: Symptomatic laboratory-confirmed COVID-19 Time: up to 6 weeksDescription: The proportion of subjects with symptomatic laboratory-confirmed VRI identified after the start of treatment and before the end of the 6-week treatment period.
Measure: Symptomatic laboratory-confirmed VRI Time: up to 6 weeksCOVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin.
Description: the estimated number of patients with decreased viral load
Measure: Number of patients with decreased viral load Time: 6 monthsTrial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers
Azithromycin has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.
Description: the number of patients with virological cure
Measure: Number of patients with virological cure Time: 6 monthsThis is a proof of concept study to evaluate the efficacy of nitazoxanide (600 mg TID) to treat hospitalized patients with non-critical COVID-19.
Description: PCR will be done to evaluate the change in viral load
Measure: Viral load Time: day 1, 4, 7, 14 and 21Description: Time to wean off oxygen supplementation
Measure: Evolution of acute respiratory syndrome Time: 21 daysDescription: WHO Ordinal Scale for Clinical Improvement that measures illness severity over time (0=uninfected; ambulatory, no limitation of activities=1; ambulatory, limitation of activities=2, hospitalized no oxygen therapy=3; hospitalized oxygen by mask or nasal prongs=4; hospitalized non invasive ventilation or high-flow oxygen=5; hospitalized intubation or mechanical ventilation=6; hospitalized ventilation + additional organ support=7; death=8)
Measure: Change in Clinical Condition Time: 21 daysDescription: Time to be discharged from hospital
Measure: Hospital discharge Time: 21 daysDescription: Evaluation of change in acute respiratory syndrome
Measure: Rate of mortality within 21-days Time: 21 daysDescription: Evaluation of change in acute respiratory syndrome
Measure: Need of mechanical ventilation Time: 21 daysThe primary objective of this study is to evaluate the efficacy of the drug nitazoxanide 600 mg, administered three times a day, in relation to placebo in preventing the development of COVID-19 in subjects from vulnerable communities that had direct contact with patients diagnosed with the disease.
Description: PCR will be done to evaluate infection
Measure: The proportion of subjects with laboratory-confirmed COVID-19 identified after start of treatment and before the end of the study Time: 28 daysDescription: Number of participants with treatment-related adverse events
Measure: Incidence of Treatment-Emergent Adverse Events Time: 28 daysDescription: Symptomatic PCR positive subjects
Measure: The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the study Time: 28 daysDescription: Asymptomatic PCR will be done to evaluate infection
Measure: The proportion of subjects with asymptomatic laboratory-confirmed COVID identified after the start of treatment and before the end of the study Time: 28 daysDescription: Subject adherence to treatment will be assessed through study diary record
Measure: Treatment adherence Time: 7 daysDescription: Proportion of patients with severe condition
Measure: Disease complication Time: 28 daysDescription: Proportion of patient that needed undergo an unscheduled visit
Measure: Incidence of subjects that underwent unscheduled visit Time: 28 daysThe aim is to demonstrate a decrease in complications among ambulatory patients who are diagnosed with mild COVID-19 by treating them with nitazoxanide for 7 to 14 days on top of standard care compared to patients who receive standard care and placebo only.
Description: Symptoms will be assessed using a 5 point scale (1- excellent, 2- good, 3- fair, 4 - poor 5 - very poor).
Measure: Change in signs and symptoms scale Time: 21 daysDescription: Number of participants with treatment-related adverse events
Measure: Incidence of Treatment-Emergent Adverse Events Time: 21 daysDescription: Change in clinical condition - WHO Ordinal Scale for Clinical Improvement that measures illness severity over time (0=uninfected; ambulatory, no limitation of activities=1; ambulatory, limitation of activities=2, hospitalized no oxygen therapy=3; hospitalized oxygen by mask or nasal prongs=4; hospitalized non invasive ventilation or high-flow oxygen=5; hospitalized intubation or mechanical ventilation=6; hospitalized ventilation + additional organ support=7; death=8)
Measure: The proportion of subjects hospitalized after start of treatment and before the end of the study Time: 21 daysDescription: Change in clinical condition - WHO Ordinal Scale for Clinical Improvement that measures illness severity over time (0=uninfected; ambulatory, no limitation of activities=1; ambulatory, limitation of activities=2, hospitalized no oxygen therapy=3; hospitalized oxygen by mask or nasal prongs=4; hospitalized non invasive ventilation or high-flow oxygen=5; hospitalized intubation or mechanical ventilation=6; hospitalized ventilation + additional organ support=7; death=8)
Measure: The proportion of subjects that need mechanical ventilation after start of treatment and before the end of the study Time: 21 daysDescription: Time required (days) to full symptom recovery
Measure: Duration of symptoms Time: 21 daysDescription: Evaluation of change in acute respiratory syndrome
Measure: Rate of mortality within 21-days Time: 21 daysEvaluation of the efficacy and safety of NTX in adult patients (≥18 years and <60 years), with SARS-CoV-2 infection with mild symptoms of COVID-19, compared to a placebo control arm. 135 patients will be randomized to either Nitazoxanide (n=90) or placebo (n=45) (2:1). Simple blind design. Primary endpoint: eradication of virus from patients' respiratory tract secretions by the 7th day of treatment.
Description: Erradication will be considered a reduction of the viral load on day 7 greater than 35% with respect to placebo. Extraction of genomic material will be performed using a QIAgen mini kit (QIAmp viral RNA) validated by the CDC (United States Center for Disease Control and Prevention (https://www.fda.gov/media/134922/download) (CDC-006-00019) Viral load will be quantified with the following detection kits: Commercial Kit: PCR-EUA-CDC-nCoV-IFU. Commercial KIT SENTINEL - STAT-NAT Covid 19B (Berlín). Rational: In mild cases of COVID-19, 50% of the patients eradicated the virus within a period of 3 weeks, 25% eradicated the virus before the 13th day, 75% during the first month and the rest were " late eradicators." This latter subgroup of patients has been associated with severe cases of COVID-19 disease.
Measure: Eradication of SARS COV-2 from patients' respiratory tract secretions by treatment day 7th. Time: 7 dayDescription: Consequently, in mild cases, viral eradication will likely occur more frequently during the first to second week of COVID-19 disease; less than 15% could eradicate the virus during the first week of symptom onset. From an epidemiological point of view, increasing the viral eradication rate from less than 15% to more than 35% during the first two weeks of treatment would be clinically relevant.(seven), 14 (fourteen) and 35 (thirty-five) after starting treatment compared to the baseline measurement.
Measure: Comparative decrease of the viral load Time: 3 - 35 daysDescription: Clinical improvement according to the WHO COVID-19 ordinal scale. Minimun 0 (zero), (best), maximum 8 (eight) (worst)
Measure: Clinical improvement Time: 1 - 35 daysDescription: Percentage of pneumonia patients meeting severity criteria.
Measure: Pneumonia patients meeting severity criteria. Time: 1 - 35 daysDescription: Number of days with fever (axillary temperature higher than 37.5°C).
Measure: Number of days with fever Time: 1 - 35 daysDescription: Percentage of patients requiring mechanical ventilation through orotracheal intubation (OT) and/or ICU hospitalization.
Measure: Patients requiring mechanical ventilation Time: 1 - 35 daysDescription: Mortality rate.
Measure: Mortality rate. Time: 1- 35 daysDescription: Lymphocyte recovery (absolute lymphocyte count > 1000 / mm3).
Measure: Lymphocyte recovery Time: 7 dayDescription: Days of ICU hospitalization.
Measure: ICU hospitalization. Time: 1 - 35 daysDescription: Oxygen saturation (SpO2) > 92% (at ambient FiO2).
Measure: Oxygen saturation Time: 1 - 35 daysDescription: Days of hospitalization
Measure: Days of hospitalization Time: 1 - 35 daysDescription: Respiratory rate per minute (in afebrile state conditions).
Measure: Respiratory rate Time: 1 - 35 daysTrial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Description: To evaluate the effect of nitazoxanide in reducing the time to sustained response compared to placebo in subjects with mild or moderate COVID-19
Measure: Reducing the Time to Sustained Response Time: Up to 21 daysDescription: To evaluate the effect of nitazoxanide in reducing the rate of progression to severe COVID-19 illness compared to placebo
Measure: Reducing the Rate of Progression Time: Up to 21 daysThe efficacy of treating COVID-19 infection by using Sofosbuvir/Ledipasvir and Nitazoxanide will be examined. Included patients will be into 3 groups. The 1st group will receive Sofosbuvir/Ledipasvir plus the standard care treatment (SCT). The 2nd group will take Nitazoxanide and SCT, while the 3rd group will receive only SCT. Then the clinical improvement and the rate of PCR change from positive to negative will be evaluated in each group.
Description: The PCR will be done at time of recruitment, day 5, 8, 11, and 14. The time taken to have negative will be measured in each group.
Measure: Change of PCR from positive to negative Time: 2 weeksDescription: Clinical improvement will be measured by detection of downgrading of cases severity according to the World Health Organization case severity classification.
Measure: Clinical improvement Time: 2 weeksDescription: All patients will be asked about any possible adverse effects that they may suffer from taken drugs during their follow up. Any mentioned side effect will be reported. Drug discontinuation and it cause will be also reported if it happened.
Measure: Adverse events Time: 2 weeks